Observations placeholder

Zonisamide - sold under the trade names Excegran and Zonegran , is an anticonvulsant in the treatment of epilepsy, approved for use as an adjunctive therapy in adults with partial-onset seizures, and generalized tonic clonic seizure. Its theoretical action is shown below

Zonisamide in the treatment of epilepsy - Holder JL, Wilfong AA.  Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030 , USA.
Introduction: Epilepsy affects approximately 3 million people in the USA and up to 2% of the worldwide population. The yearly direct medical cost of epilepsy in the USA alone is estimated to be $9.5 billion. Epilepsy affects both children and adults and can significantly impair quality of life.
Zonisamide is a second-generation antiepileptic drug (AED) that has …. simpler dosing than earlier drugs.
Areas covered: The history of the development of zonisamide is reviewed in this paper. The data available demonstrating zonisamide's mechanism of action as:

• a voltage-gated sodium channel inhibitor

• a T-type calcium channel inhibitor

• an enhancer of GABA release

• and an inhibitor of glutamate release

its actual action according to eHealthme ADRs:  Most common Zonisamide side effects

• Convulsion - (418 reports)
• Drug ineffective - (296 reports)
• Fever - (224 reports)
• Erythema multiforme - (180 reports)
• Fatigue - (159 reports)
• Rashes - (151 reports)
• Fall - (150 reports)
• Dizziness - (146 reports)
• Nausea and vomiting - (146 reports)
• Drowsiness - (144 reports)